Pregabalin

Formulation

The table below describes the formulation of pregabalin and the controls morphine sulfate and gabapentin for the following in vivo experiments.

Experiment(s) Compound Dose(s) mg/kg Correction factor Dose volume mL/kg Route Vehicle Suspension / Solution
Pharmacokinetics Pregabalin 30 1.00 1 PO Saline Solution
Irwin, Rotarod Pregabalin 10, 30, 60, 100 1.00 5 PO Saline Solution
Plantar incision, MIA Pregabalin 10, 30, 60 1.00 5 PO Saline Solution
L5/L6 SNL Pregabalin 10, 30, 60 1.00 1 PO Saline Solution
Plantar incision, Morphine 6 1.33 1 SC Saline Solution
L5/L6 SNL (Acetone), MIA
L5/L6 SNL (von Frey) Gabapentin 60 1.00 1 PO Saline Solution

L5/L6 SNL = L5/L6 spinal nerve ligation; MIA = monosodium iodoacetate; PO = per os; SC = subcutaneous


Results

Expand and Collapse accordion content

Method: Protein Binding
A table shows the results of rapid equilibrium dialysis to assess protein binding and percent recovery of pregabalin. In rat plasma, pregabalin was 4.2% bound to protein and 95.8% unbound and had a recovery of 123.7%. In rat brain homogenate, pregabalin was 7% bound to protein and 93% unbound and had a recovery of 124.1%. Acebutolol, quinidine, and warfarin were included in the study as controls and returned values consistent with literature values.

Method: Rat Rotarod Animals were balanced across treatment groups based on body weight. Animals that achieved a latency of 40 seconds during the baseline trial were included in the study. Experimenters assessing behavior were masked to treatment. Group size was determined using power analysis.
Two graphs show the latency for male or female rats to fall off a rotarod apparatus. Responses are shown at the following time points: baseline (before treatment) and at 1, 2, 4, and 6 hours after treatment with vehicle (saline, delivered PO) or pregabalin (10, 30, 60, or 100 mg/kg, delivered PO). There were 10 rats per group. Neither males nor females had a significant interaction of time x treatment in a two-way repeated measures ANOVA, but a significant effect of treatment was found for each sex. Bonferroni’s tests found a significant decrease in the latency to fall relative to vehicle in males after treatment with 60 mg/kg pregabalin (p<0.01) and 100 mg/kg pregabalin (p<0.0001). Bonferroni’s tests found a significant decrease in the latency to fall relative to vehicle in females after treatment with 30 mg/kg pregabalin (p<0.01), 60 mg/kg pregabalin (p<0.05), and 100 mg/kg pregabalin (p<0.0001).


This work was conducted by PsychoGenics Inc. (Paramus, NJ) in collaboration with PSPP, NINDS, NIH under contract # 75N95019D00026. Prescribing information for clinically used controls can be found at labels.fda.gov. Information for icons representing experimental design details can be found through the NINDS Office of Research Quality https://go.nih.gov/Yw2tHGI.